Brammer Bio Launches as a New Biologics CDMO
Brammer Biopharmaceuticals has merged with Florida Biologix to create a cell and gene therapy biologics contract development and manufacturing organization (CDMO). The merged company, Brammer Bio, will provide process development, clinical manufacturing, and commercial manufacturing. Ampersand Capital Partners, the majority shareholder of Florida Biologix, made an additional investment in the combined company and is the only institutional investor in Brammer Bio.
Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications, along with process and analytical development, and regulatory support. Brammer Bio occupies 45,000 square feet of process development and Phase I/II clinical manufacturing space in Alachua, Florida, and is developing a 50,000 square foot facility in Lexington, Massachusetts, with plans to build-out large-scale, Phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and quality control and analytical laboratories for clinical and commercial launch services.
The management team is led by Mark Bamforth, president and CEO, and Steven Kasok, chief financial officer, who were previously co-founders of Gallus Biopharmaceuticals, and Dr. Richard Snyder, CSO, the founder of Florida Biologix, which was spun out of the University of Florida in 2015.
Source: Brammer Bio